在四家欧洲医院的结核分枝杆菌临床分离株对苯并噻嗪酮均具有一致的敏感性。
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.
机构信息
University of Pavia, Department of Genetics and Microbiology, Via Ferrata 1, 27100 Pavia, Italy.
出版信息
Antimicrob Agents Chemother. 2010 Apr;54(4):1616-8. doi: 10.1128/AAC.01676-09. Epub 2010 Jan 19.
Abstract
The new antitubercular drug candidate 2-[2-S-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (BTZ043) targets the DprE1 (Rv3790) subunit of the enzyme decaprenylphosphoryl-beta-d-ribose 2'-epimerase. To monitor the potential development of benzothiazinone (BTZ) resistance, a total of 240 sensitive and multidrug-resistant Mycobacterium tuberculosis clinical isolates from four European hospitals were surveyed for the presence of mutations in the dprE1 gene and for BTZ susceptibility. All 240 strains were susceptible, thus establishing the baseline prior to the introduction of BTZ043 in clinical trials.
摘要
新型抗结核候选药物 2-[2-S-甲基-1,4-二恶烷-8-氮杂螺[4.5]癸-8-基]-8-硝基-6-(三氟甲基)-4H-1,3-苯并噻嗪-4-酮（BTZ043）靶向酶去烯丙基磷酸-β-D-核糖 2'-差向异构酶的 DprE1（Rv3790）亚基。为了监测苯并噻嗪酮（BTZ）耐药性的潜在发展，对来自四家欧洲医院的 240 株敏感和多药耐药结核分枝杆菌临床分离株进行了 dprE1 基因突变检测和 BTZ 敏感性检测。所有 240 株菌株均敏感，从而在 BTZ043 临床试验之前建立了基线。
相似文献
1
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.
Antimicrob Agents Chemother. 2010 Apr;54(4):1616-8. doi: 10.1128/AAC.01676-09. Epub 2010 Jan 19.
2
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
Science. 2009 May 8;324(5928):801-4. doi: 10.1126/science.1171583. Epub 2009 Mar 19.
3
Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6451-6459. doi: 10.1128/AAC.01523-16. Print 2016 Nov.
4
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2012 Nov;56(11):5790-3. doi: 10.1128/AAC.01476-12. Epub 2012 Aug 27.
5
The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2015 Aug;59(8):4446-52. doi: 10.1128/AAC.00778-15. Epub 2015 May 18.
6
Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.
Curr Med Chem. 2010;17(27):3099-108. doi: 10.2174/092986710791959693.
7
Mutations in Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0090422. doi: 10.1128/aac.00904-22. Epub 2022 Aug 3.
8
Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis.
J Am Chem Soc. 2010 Oct 6;132(39):13663-5. doi: 10.1021/ja106357w.
9
Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.
Eur J Med Chem. 2020 Dec 15;208:112773. doi: 10.1016/j.ejmech.2020.112773. Epub 2020 Aug 30.
10
Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.
Tuberculosis (Edinb). 2018 Jul;111:31-34. doi: 10.1016/j.tube.2018.04.007. Epub 2018 Apr 25.
引用本文的文献
1
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
J Antimicrob Chemother. 2025 May 2;80(5):1315-1323. doi: 10.1093/jac/dkaf076.
2
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis.
Nat Commun. 2025 Jan 18;16(1):826. doi: 10.1038/s41467-025-56146-9.
3
DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid.
Nat Commun. 2023 Jun 28;14(1):3828. doi: 10.1038/s41467-023-39300-z.
4
Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside Granulomas in the Guinea Pig Model.
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0143822. doi: 10.1128/aac.01438-22. Epub 2023 Mar 28.
5
Assay development and inhibition of the -DprE2 essential reductase from .
Microbiology (Reading). 2023 Jan;169(1). doi: 10.1099/mic.0.001288.
6
Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine.
J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jan 15;1215:123555. doi: 10.1016/j.jchromb.2022.123555. Epub 2022 Dec 9.
7
Antituberculosis Macozinone Extended-Release Tablets To Enhance Bioavailability: a Pilot Pharmacokinetic Study in Beagle Dogs.
Microbiol Spectr. 2023 Feb 14;11(1):e0232722. doi: 10.1128/spectrum.02327-22. Epub 2022 Dec 12.
8
Recent Advances of DprE1 Inhibitors against : Computational Analysis of Physicochemical and ADMET Properties.
ACS Omega. 2022 Nov 3;7(45):40659-40681. doi: 10.1021/acsomega.2c05307. eCollection 2022 Nov 15.
9
Repurposing the Pathogen Box compounds for identification of potent anti-malarials against blood stages of Plasmodium falciparum with PfUCHL3 inhibitory activity.
Sci Rep. 2022 Jan 18;12(1):918. doi: 10.1038/s41598-021-04619-4.
10
Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening.
Acta Pharmacol Sin. 2022 Jun;43(6):1605-1615. doi: 10.1038/s41401-021-00779-1. Epub 2021 Oct 19.
本文引用的文献
1
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.
PLoS Pathog. 2009 Oct;5(10):e1000645. doi: 10.1371/journal.ppat.1000645. Epub 2009 Oct 30.
2
Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community.
Curr Opin Infect Dis. 2009 Feb;22(1):11-7. doi: 10.1097/QCO.0b013e3283210020.
3
Mycobacterium tuberculosis: drug resistance and future perspectives.
Future Microbiol. 2009 Jun;4(5):597-614. doi: 10.2217/fmb.09.20.
4
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
Science. 2009 May 8;324(5928):801-4. doi: 10.1126/science.1171583. Epub 2009 Mar 19.
5
Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy.
FEBS J. 2008 Jun;275(11):2691-711. doi: 10.1111/j.1742-4658.2008.06395.x. Epub 2008 Apr 15.
6
The biological cost of mutational antibiotic resistance: any practical conclusions?
Curr Opin Microbiol. 2006 Oct;9(5):461-5. doi: 10.1016/j.mib.2006.07.002. Epub 2006 Aug 4.
7
Genes required for mycobacterial growth defined by high density mutagenesis.
Mol Microbiol. 2003 Apr;48(1):77-84. doi: 10.1046/j.1365-2958.2003.03425.x.
Zotero 插件